WO2005071082A1 - 抗癌作用を有するアンチセンスオリゴヌクレオチド - Google Patents
抗癌作用を有するアンチセンスオリゴヌクレオチド Download PDFInfo
- Publication number
- WO2005071082A1 WO2005071082A1 PCT/JP2004/015932 JP2004015932W WO2005071082A1 WO 2005071082 A1 WO2005071082 A1 WO 2005071082A1 JP 2004015932 W JP2004015932 W JP 2004015932W WO 2005071082 A1 WO2005071082 A1 WO 2005071082A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antisense oligonucleotide
- rna
- cancer
- cells
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Definitions
- the present invention relates to an antisense oligonucleotide having an anticancer action, for example, a cancer cell growth inhibitory action, a cancer therapeutic or preventive action, etc., and a cancer cell growth inhibitor comprising the antisense oligonucleotide. And a therapeutic or preventive agent for cancer.
- SRP recognition particle
- SRP has a sedimentation coefficient of 1 IS as a whole, and consists of 7SL RNA and 6 types of proteins.
- a ribosome is a place for protein synthesis, and it also has rRNA and many ribosomal protein forces.
- a force with a sedimentation coefficient of 80S as a whole is further split into two particles of 60S and 40S, and the former 5S, 5.8S and 28S rRNA, and the latter ⁇ 18S r Contains 1 molecule each of RNA.
- SRP recognizes a signal peptide having a hydrophobic amino acid sequence that exists at or near the N-terminus of a secreted protein precursor that has also extended its ribosome force, and binds to a protein-ribosome complex. Thereby, the translation of the protein ahead is stopped. SRP transports the complex to the membrane of the endoplasmic reticulum and binds to the SRP receptor protein on the cytosolic side of the endoplasmic reticulum. When SRP-bound complexes bind to the membrane, translation inhibition is released, SRP dissociates, and ribosomes are immobilized on the membrane. Translation is then continued, and the polypeptide chain passes through the membrane, creating a mature secreted protein.
- RNAs in the nucleus of eukaryotic cells, in addition to mRNA involved in protein translation as described above, a group of RNAs called small nuclear RNAs of about 100-300 bases in length are synthesized. Is done. They usually exist as ribonucleoproteins in association with proteins.
- nuclear low molecular weight RNAs for example, RNAs called Ul, U2, U3, U4, U5, and U6 are known.
- Ul, U2, U4, U5, and U6 are known.
- the functions of small nuclear RNA are Ul, U2, U4, U5, and U6 before mRNA. It has been shown to be involved in the splicing of the precursor, but other functions are still unknown.
- transcripts [Transforming RNA (Transforming RNA) added with poly (A) to the base sequence (SEQ ID NO: 2) on the 3 'end of the first stem in the secondary structure of U5 RNA and transcribed in an RNA polymerase II-dependent manner. RNA)] was also shown to have canceration ability (see Non-Patent Document 2). Canceration ability depended on a specific base sequence (SEQ ID NO: 3) in the transforming RNA.
- Non-Patent Document 2 Mol. Carcinog. 20, 175-188 (1997)
- Non-Patent Document 3 J. Biol. Chem. 274 (22), 15786-15796 (1999)
- the present invention relates to an antisense oligonucleotide having an anticancer effect, for example, a cancer cell proliferation inhibitory effect, a cancer treatment or preventive effect, and the like, and a cancer cell proliferation inhibitor comprising the antisense oligonucleotide.
- Another object is to provide a therapeutic or preventive agent for cancer.
- the antisense oligonucleotide for the 47-51 base sequence of RNA is the U5
- RNA can be remarkably effective in suppressing canceration, and the present invention has been completed.
- the present invention exerts a lethal and growth-inhibiting action on human cancer cells based on the elucidation of the initial function associated with canceration ability of U5 RNA and transforming RNA derived from U5 RNA. It was made by searching and clarifying substances that act antagonistically.
- the present invention provides:
- a cancer cell proliferation inhibitor comprising the antisense oligonucleotide according to [1] or [2],
- a therapeutic or prophylactic agent for cancer comprising the antisense oligonucleotide according to [1] or [2],
- cancer cell proliferation can be suppressed or killed, cancer symptoms can be alleviated or ameliorated, or cancer can be treated or prevented.
- FIG. 1 is a schematic diagram of the structure of 7SL RNA of SRP derived from rabbit cells. The numbers in the figure indicate the base positions (except 3 'and 5').
- FIG. 2 is a graph showing the effect of oligol-5, which is an antisense oligonucleotide prepared in Examples, on the proliferation of human cancer cells.
- FIG. 3 is a graph showing the concentration-dependent effect of oligo3 on the proliferation of human cancer cells.
- FIG. 4 is a graph showing the effect of oligol-5 on cellular DNA synthesis in human cancer cells.
- FIG. 5 is a graph showing the effect of oligo3 on the death of human cancer cells.
- FIG. 6 is a graph showing the effect of oligo3 on body weight gain of mice when administered intravenously at gZg body weight.
- nucleotide is used in the meaning including DNA and RNA.
- antisense oligonucleotide refers to an oligonucleotide having a base sequence complementary to a specific base sequence (hereinafter referred to as a sense sequence) and capable of hybridizing to the sense sequence.
- the sense sequence corresponding to the antisense oligonucleotide of the present invention is 7SL R of SRP.
- This is the 47-51 base sequence of NA.
- Fig. 1 schematically shows the structure of 7SL RNA of SRP derived from rabbit cells.
- the base sequence of 7SL RNA is known from various animal cells.
- non-patent literature 3 describes the ones derived from the rabbit cells, and Ullu, E "and Wiener, AM, (1984) EMBO J. 3. 3303-3310.
- the above-mentioned 7SL RNA 47 The base sequence at position 51 is the same.
- the antisense oligonucleotide of the present invention has an anticancer effect such as a cancer cell growth inhibitory effect, a cancer therapeutic or preventive effect, and the like.
- antisense oligonucleotides comprising the nucleotide sequence set forth in SEQ ID NO: 1 are useful.
- Cancer cell growth inhibitory effects include cancer cell killing effects. It is presumed that the shift effect of the antisense oligonucleotide of the present invention is also based on the suppressive action of the U5 RNA such as canceration ability.
- the cancer cell proliferation inhibitory action of the antisense oligonucleotide of the present invention can be confirmed according to the method described in the examples described later.
- the method for synthesizing the antisense oligonucleotide of the present invention is not particularly limited, and includes a phosphoramidite method, a phosphorothioate method, a phosphotriester method and the like using a known oligonucleotide synthesizer. Can be used.
- the phosphate group or the hydroxyl group of the ribose moiety may be replaced with other stable groups within a range that does not significantly reduce the activity. It is also possible to use it as a derivative substituted.
- Specific examples of such antisense oligonucleotide derivatives include those in which the phosphate group is substituted with a thiophosphate group or a methylphosphonate group, the hydroxyl group of the ribose moiety is an alkoxy group such as a methoxy group or a aryloxy group, Examples thereof include those substituted with an amino group or a fluorine atom.
- the sequence of the bases constituting it is important.
- the oligonucleotide has a non-natural type as described above.
- it may be a peptide nucleic acid type modifying compound (PNA). Because the permeability of cell membrane and nuclear membrane is good, as the antisense oligonucleotide of the present invention, those having a sugar (preferably bentose) structure in their structure are preferred.
- the antisense oligonucleotide of the present invention may be DNA type or RNA type, but it is preferable that the viewpoint of higher stability when administered to a living body is also the DNA type. .
- the antisense oligonucleotide of the present invention can be used alone. Therefore, the cancer cell growth inhibitor and the therapeutic or preventive agent for cancer (hereinafter sometimes collectively referred to as a preparation) provided by the present invention may have the ability of the antisense oligonucleotide itself, Preferably prepared by mixing with a pharmaceutically acceptable substance and preparing the preparation according to a known method.
- Cancer cell growth inhibitors and cancer therapeutic agents or preventive agents are not particularly distinguished in terms of their composition and production method, but cancer cell growth inhibitors are used to alleviate or improve cancer symptoms, In addition to being used for the treatment or prevention of cancer, for example, it is different in that it is also intended to be used for suppressing cancer cell growth as a general reagent in a normal experimental process.
- the preparation can be produced, for example, as follows.
- the antisense oligonucleotide of the present invention in water, physiological saline, glucose solution or the like, and if desired, a buffer, preservative or stable. It may contain an agent!
- the antisense oligonucleotide of the present invention can be prepared by dissolving or dispersing in an oily, emulsion or water-soluble base, and if desired, a stabilizing agent, PH adjusters, plasticizers, emulsifiers, surfactants, solubilizers, wetting agents, preservatives, preservatives, solvents or absorption accelerators may be included.
- an emulsion, lotion or the like is prepared by dissolving or dispersing the antisense oligonucleotide of the present invention in an aqueous phase and emulsifying it with an oil phase component such as a hydrocarbon or a higher alcohol.
- an oil phase component such as a hydrocarbon or a higher alcohol.
- a stabilizer, a pH adjuster, a plasticizer, an emulsifier, a surfactant, a solubilizer, a wetting agent, a preservative, a preservative, a solvent, or an absorption enhancer may be contained.
- the cell growth inhibitor of the present invention includes, for example, water as a general reagent. It can also be prepared as a dry product that can easily be made into a solution.
- the preparation is preferably combined with a known pharmaceutically acceptable carrier.
- the carrier include a carrier mainly composed of lipids such as ribosome, fat emulsion and micelle, a peptide carrier such as polylysine and polyorthin, and a synthetic polymer such as polyethyleneimine and polylactic acid Z glycolic acid copolymer.
- carriers include carriers.
- preparations combined with ribosomes are preferred.
- the antisense oligonucleotides of the invention are preferably present embedded in ribosomes. Formulation using these carriers can be performed according to a known method.
- Preparations combined with ribosomes are phospholipids, glycolipids, neutrals commonly used for ribosome formation.
- lipids such as lipids
- substances that give cationic charge to the formed liposomes such as dicetyl phosphate, stearylamine, and substances that prevent oxidation of ribosomes, such as ⁇ -tocopherol
- compositions may contain other known ingredients that have been shown to have anticancer effects.
- the antisense oligonucleotide of the present invention linked to a vector that is, incorporated into an arbitrary vector can be used.
- the antisense oligonucleotide is preferably operably linked to a suitable promoter.
- “operably” means that the antisense oligonucleotide (RNA) can be expressed in cells of a living body by the action of a promoter.
- a vector for example, an adenovirus vector, a vaccinia virus vector, a retrovirus vector etc. are mentioned.
- Such a vector is useful as a vector for gene therapy.
- Sambrook, J., et. Al. Molecular cloning: A Laboratory Mannual;.. 2 nd Ed , Cold Spring Harbor Laboratory Cold Spring Harbor.
- the content of the antisense oligonucleotide in the preparation of the present invention is not particularly limited, and may be appropriately adjusted so as to obtain a desired effect according to the use mode corresponding to each preparation. 1 to 10% by weight is appropriate.
- the cancer cell growth inhibitor and the cancer therapeutic or prophylactic agent of the present invention are obtained.
- the antisense oligonucleotide of the present invention for producing the cancer cell proliferation inhibitor of the present invention, or a therapeutic or preventive agent for cancer.
- Examples of the method of administering the therapeutic or prophylactic agent for cancer of the present invention to a living body include, for example, oral administration, intravenous administration, transdermal administration, topical administration, depending on the form of the therapeutic agent or prophylactic agent. Administration, intraperitoneal administration, and the like can be mentioned, but are not particularly limited.
- a method for administering the therapeutic or prophylactic agent for cancer of the present invention a more effective method may be selected according to each individual, the state of each disease, etc., but intravenous administration is usually preferable.
- the dose of the therapeutic or preventive agent for cancer is not particularly limited as long as it is appropriately determined according to symptoms, etc.
- the present invention for In terms of the amount of the antisense oligonucleotide, 0.1-1 mgZkg body weight, more preferably 0.1-0.5 mgZkg body weight is appropriate.
- the administration may be performed once or divided into multiple times within a day. Also, the administration period is not particularly limited.
- the living body to which the therapeutic or preventive agent for cancer of the present invention is administered is not limited to the above-mentioned humans, and includes, for example, mammals other than humans.
- the cancer cell proliferation inhibitor of the present invention can be used in the same manner as the therapeutic or preventive agent for cancer of the present invention.
- the location of cancer cells that are targets of anticancer activity by the cancer cell proliferation inhibitor and the therapeutic or preventive agent for cancer according to the present invention is not particularly limited. It is preferably derived from the digestive tract such as the surface, esophagus, stomach and large intestine, liver that can be administered intraarterially, and the like.
- the antisense oligonucleotide of the present invention includes, for example, the reference example 1 described later. In particular, no toxicity is observed.
- antisense ODN SEQ ID NO: 6
- the antisense ODN acts in a direction to reduce the inhibition of secretory protein synthesis, the antisense ODN is expected to work in canceration.
- an antisense oligonucleotide for a base sequence consisting of several residues centered on the 48-51 base sequence (SEQ ID NO: 8) of the 7SL RNA of the Rabbit cell-derived SRP was used.
- SEQ ID NO: 8 the base sequence of 7SL RNA derived from human cells.
- An antisense oligonucleotide (DNA) having the base sequence shown in Table 1 below was prepared by requesting Takara Bio Inc.
- oligol-5 indicates the name of the antisense oligonucleotide, and the number in parentheses indicates the corresponding position of the base sequence of 7SL RNA.
- Oligo5 is a mixture of antisense oligonucleotides randomly generated without being based on the base sequence of 7SL RNA, and N represents A, C, G or T.
- oligo 5 NNNNN [0043] The influence of each oligo on cell proliferation was examined. That is, HeLa cells, which are human cancer cells in DMEM medium containing 10% heat-inactivated fetal calf serum (FCS), were seeded in a 96-well plate at a density of 1500 cells. After culturing for 24 hours, the culture solution was replaced with a culture solution containing each oligo and 1% FCS at a concentration of 10 M. Culturing was performed at 37 ° C in the presence of CO. That
- FIG. 2 is a graph showing the effect of each oligo on the proliferation of human cancer cells. The experiment was performed in triplicate. In the graph, each data is shown as average person SD (hereinafter the same). It can be seen that oligo3 has a strong growth inhibitory effect on human cancer cells with the lowest cell viability. Incidentally, 1, 2, 3, and 4 each Itoda cells viability ⁇ or control ⁇ to 49.6 0/0, 62.7%, 71.6%, and 71. was 1%.
- Fig. 3 is a graph showing the concentration-dependent effect of oligo3 on the proliferation of human cancer cells. It can be seen that oligo3 growth inhibition of human cancer cells increases in proportion to the concentration. The cell viability on days 1, 2, 3, and 4 was 44.4%, 45.1%, 55.5%, and 63.8% of the control.
- each oligo on cellular DNA synthesis was examined by observing [3 ⁇ 4] methylthymidine uptake by cells. That is, after culturing the cells for 24 hours in the same manner as described above, the culture solution was replaced with a culture solution containing each oligo at a concentration of 5, 10 or 20 M and 0.1% FCS. After 18 hours: CiZmL of [] methylthymidine was added to the culture and further incubated for 6 hours. After the culture, the specific radioactivity of the cells was determined by a liquid scintillation counter after a predetermined treatment.
- FIG. 4 is a graph showing the effect of each oligo on cellular DNA synthesis in human cancer cells.
- oligo3 has the lowest uptake of [] methylthymidine into cells and has a strong effect of suppressing the growth of human cancer cells.
- oligo3 the induction of cell death in human cancer cells by oligo3 was examined. That is, 3000 HeLa cells were seeded in the slide chamber. After culturing for 24 hours, the culture solution was replaced with a culture solution containing oligo3 at a concentration of 20 M. About 18 hours after the addition of oligo3, the cultured cells were observed with a stereomicroscope (magnification 100 times; manufactured by Olympus), and the process of cell rounding and cell death was observed. Furthermore, 24 hours after the addition of oligo3, Giemsa staining was performed after washing the cells with phosphate buffered saline (PBS). The number of viable and dead cells was measured. The rate (%) was determined. As a control, Sako oligo5 was used.
- PBS phosphate buffered saline
- FIG. 5 is a graph showing the effect of oligo3 on the death of human cancer cells.
- Cell viability with oligo3 is 30.8%, whereas control and oligo5 are 98.5% and 98.7%, respectively, and cell viability with oligo3 is significantly lower than other controls. Therefore, oligo3 has a high cell death-inducing effect on human cancer cells.
- oligo3 (SEQ ID NO: 1), an antisense oligonucleotide to the 47-51 base sequence of SRP 7SL RNA, suppresses the growth of cancer cells and induces their death. It turns out that it has an effect
- oligo3 The toxicity of oligo3 was examined. That is, 20 g per lg body weight was intravenously administered to female mice (5 weeks old) using oligo3 dissolved in physiological saline so as to be 1 mgZmL. The body weight of mice was measured on the day of administration (day 0) and 2, 5, 10, 12 and 14 days after administration.
- Fig. 6 is a graph showing the effect of oligo3 on body weight gain of mice when intravenously administered at 20 ⁇ g Zg body weight. In the graph, each data is indicated by average person SE. Each data was obtained using 7 mice for oligo3 and 6 mice for control.
- an antisense oligonucleotide having an anticancer effect for example, a cancer cell growth inhibitory effect, a cancer treatment or preventive effect, and the like, and a cancer cell growth inhibitor comprising the antisense oligonucleotide and A therapeutic or prophylactic agent for cancer is provided.
- an anticancer effect for example, a cancer cell growth inhibitory effect, a cancer treatment or preventive effect, and the like
- a cancer cell growth inhibitor comprising the antisense oligonucleotide and A therapeutic or prophylactic agent for cancer
- SEQ ID NO: 1 is the base sequence of an antisense oligonucleotide corresponding to the base sequence at positions 47 to 51 of 7SL RNA.
- SEQ ID NO: 3 is a partial base sequence of transforming RNA.
- SEQ ID NO: 4 is the base sequence of an oligodeoxynucleotide prepared based on the partial base sequence of transforming RNA.
- SEQ ID NO: 5 is a partial base sequence of an oligonucleotide.
- SEQ ID NO: 6 is the base sequence of antisense oligodeoxynucleotide relative to the base sequence of oligodeoxynucleotide.
- SEQ ID NO: 7 is a partial base sequence of an antisense oligonucleotide.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2004800187313A CN1816626B (zh) | 2004-01-22 | 2004-10-27 | 具有抗癌作用的反义寡核苷酸 |
EP04793044A EP1707630B1 (en) | 2004-01-22 | 2004-10-27 | Antisense oligonucleotide having anticancerous activity |
US10/558,265 US7393951B2 (en) | 2004-01-22 | 2004-10-27 | Antisense oligonucleotide having anticancerous activity |
JP2005517190A JP4226006B2 (ja) | 2004-01-22 | 2004-10-27 | 抗癌作用を有するアンチセンスオリゴヌクレオチド |
AT04793044T ATE428786T1 (de) | 2004-01-22 | 2004-10-27 | Antisense-oligonukleotid mit antikrebsaktivität |
DE602004020677T DE602004020677D1 (de) | 2004-01-22 | 2004-10-27 | Antisense-oligonukleotid mit antikrebsaktivität |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-014883 | 2004-01-22 | ||
JP2004014883 | 2004-01-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005071082A1 true WO2005071082A1 (ja) | 2005-08-04 |
Family
ID=34805433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/015932 WO2005071082A1 (ja) | 2004-01-22 | 2004-10-27 | 抗癌作用を有するアンチセンスオリゴヌクレオチド |
Country Status (7)
Country | Link |
---|---|
US (1) | US7393951B2 (ja) |
EP (1) | EP1707630B1 (ja) |
JP (1) | JP4226006B2 (ja) |
CN (1) | CN1816626B (ja) |
AT (1) | ATE428786T1 (ja) |
DE (1) | DE602004020677D1 (ja) |
WO (1) | WO2005071082A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007035962A2 (en) * | 2005-09-23 | 2007-03-29 | California Institute Of Technology | Gene blocking method |
CN109517894B (zh) * | 2018-08-31 | 2020-01-21 | 清华大学 | 一种与肝癌相关的非编码rna生物标志物及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994008003A1 (en) | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
US5985558A (en) * | 1997-04-14 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos |
US5827705A (en) * | 1996-03-22 | 1998-10-27 | South Alabama Medical Science Foundation | Molecule and method for importing DNA into a nucleus |
US6130207A (en) * | 1997-11-05 | 2000-10-10 | South Alabama Medical Science Foundation | Cell-specific molecule and method for importing DNA into a nucleus |
EP1049772A1 (en) * | 1998-01-30 | 2000-11-08 | Genesense Technologies, Inc. | Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth |
AU2002217932A1 (en) * | 2000-12-01 | 2002-06-11 | Origene Technologies Inc | Prostate polynucleotides and uses |
US20030232443A1 (en) * | 2002-06-18 | 2003-12-18 | Isis Pharmaceuticals Inc. | Antisense modulation of centromere protein B expression |
-
2004
- 2004-10-27 CN CN2004800187313A patent/CN1816626B/zh not_active Expired - Fee Related
- 2004-10-27 AT AT04793044T patent/ATE428786T1/de not_active IP Right Cessation
- 2004-10-27 WO PCT/JP2004/015932 patent/WO2005071082A1/ja active Application Filing
- 2004-10-27 JP JP2005517190A patent/JP4226006B2/ja active Active
- 2004-10-27 EP EP04793044A patent/EP1707630B1/en active Active
- 2004-10-27 DE DE602004020677T patent/DE602004020677D1/de active Active
- 2004-10-27 US US10/558,265 patent/US7393951B2/en active Active
Non-Patent Citations (3)
Title |
---|
HAMADA K. ET AL.: "Effect of transforming RNA on the synthesis of a protein with a secretory signal sequence in vitro", J. BIOL. CHEM., vol. 274, no. 22, 1999, pages 15786 - 15796, XP002984437 * |
LIU L. ET AL.: "The trypanosomatid signal recognition particle consists of two RNA moleculaes, a 7SL RNA homologue and a novel tRNA-like molecule", J. BIOL. CHEM., vol. 278, no. 20, 2003, pages 18271 - 18280, XP002984439 * |
ULLU E. ET AL.: "Alu sequences are processed 7SL RNA genes", NATURE, vol. 312, no. 5990, 1984, pages 171 - 172, XP002984438 * |
Also Published As
Publication number | Publication date |
---|---|
EP1707630A4 (en) | 2007-01-24 |
US7393951B2 (en) | 2008-07-01 |
JPWO2005071082A1 (ja) | 2007-12-27 |
US20070129318A1 (en) | 2007-06-07 |
EP1707630B1 (en) | 2009-04-15 |
CN1816626A (zh) | 2006-08-09 |
CN1816626B (zh) | 2010-05-26 |
ATE428786T1 (de) | 2009-05-15 |
EP1707630A1 (en) | 2006-10-04 |
DE602004020677D1 (de) | 2009-05-28 |
JP4226006B2 (ja) | 2009-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2281041B1 (en) | Silencing of csn5 gene expression using interfering rna | |
AU2002255285B2 (en) | Circular dumbbell decoy oligodeoxynucleotides (CDODN) containing DNA bindings sites of transcription | |
IL195181A (en) | Compositions for inhibiting the expression of the pcsk9 gene | |
CA2163234A1 (en) | Inhibition of proliferation of vascular smooth muscle cell | |
KR20180018405A (ko) | 세포투과성이 향상된 펩티드 핵산 복합체 및 이를 포함하는 약학적 조성물 | |
CA2677176A1 (en) | Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides | |
KR20150006743A (ko) | 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물 | |
KR20150006742A (ko) | 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물 | |
WO2018084168A1 (ja) | 皮膚線維症処置剤 | |
WO2011010691A1 (ja) | Phd2発現抑制物質搭載ポリイオンコンプレックス | |
AU2019375245B2 (en) | Composition for preventing or treating atopic dermatitis comprising skin-penetrating nucleic acid complex as effective component | |
WO2005071082A1 (ja) | 抗癌作用を有するアンチセンスオリゴヌクレオチド | |
WO2011065677A2 (ko) | 암 치료용 약학 조성물 | |
JPH10506003A (ja) | プレイオトロフィンのアンチセンスオリゴヌクレオチド | |
KR20190132220A (ko) | 매트릭스메탈로프로티나제-1 안티센스 올리고뉴클레오티드 | |
KR20220070206A (ko) | 혈소판 감소증 치료용 핵산 분자 및 그의 이용 | |
JPWO2004027061A1 (ja) | 抗増殖性疾患治療薬のスクリーニング法 | |
WO2022197607A2 (en) | Methods of cancer treatment by delivery of sirnas against bclxl and mcl1 using a polypeptide nanoparticle. | |
EP4093870A1 (en) | Compositions for the treatment of nash and associated disorders and methods of using same | |
EP4110921A1 (en) | Chemically modified transfer rna-derived small rnas (tsrnas) to target pathogenic bacteria | |
KR101722948B1 (ko) | 리간드가 결합된 이중나선 올리고 rna 구조체 및 그 제조방법 | |
GB2574845A (en) | Therapeutically active complexes | |
JP2003192692A (ja) | Vegfアンチセンス化合物 | |
JP2006111540A (ja) | リポソーム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005517190 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004793044 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007129318 Country of ref document: US Ref document number: 10558265 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048187313 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004793044 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10558265 Country of ref document: US |